Cargando…

A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India

In this communication, the authors discuss the issue of individualization of thyrotropin suppressive therapy in differentiated thyroid carcinoma (DTC) patients and share their views with respect to optimizing the dose of levothyroxine (LT) prescription both during discharge from radioiodine therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Sandip, Abhyankar, Amit, Asopa, Ramesh, Chaukar, Devendra, DCruz, Anil K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764683/
https://www.ncbi.nlm.nih.gov/pubmed/24019666
_version_ 1782283171743662080
author Basu, Sandip
Abhyankar, Amit
Asopa, Ramesh
Chaukar, Devendra
DCruz, Anil K
author_facet Basu, Sandip
Abhyankar, Amit
Asopa, Ramesh
Chaukar, Devendra
DCruz, Anil K
author_sort Basu, Sandip
collection PubMed
description In this communication, the authors discuss the issue of individualization of thyrotropin suppressive therapy in differentiated thyroid carcinoma (DTC) patients and share their views with respect to optimizing the dose of levothyroxine (LT) prescription both during discharge from radioiodine therapy ward and during follow-up. The changing management paradigm at our Institute during post-thyroidectomy period and during the preparation for radioiodine scan is also briefly highlighted. Five factors can be identified as important determinants for the dose individualization approach: (1) Persistence or absence of metastatic disease, (2) the risk characteristics of the patient and the tumor (3) patient's clinical profile, symptomatology, and contraindications (4) the feasibility to ensure a proper thyroid stimulating hormone TSH suppression level (depends on patient's socio-economic and educational background, the connectivity with the local physician and his expertise) (5) time period elapsed since initial diagnosis. While discussing each individual case scenario, the authors, based upon their experience in one of the busiest thyroid cancer referral centers in the country, discuss certain unaddressed points in the current guideline recommendations, deviations made and some challenges toward employing them into practice, which could be situation and center specific. In addition to these, the value of clinical examination, patient profile and detailed enquiry about clinical symptomatology by the attending physician in each follow-up visit cannot be overemphasized. According to the authors, this aspect, quite important for dose determination in an individual, is relatively underrepresented in the present guidelines. It would also be worthwhile to follow a conservative approach (till clear data emerges) in patients who have characteristics of “high-risk” disease, but are clinically and biochemically disease free, if no medical contraindications exist and patient tolerates the suppressive therapy well. This would be particularly applicable in the presence of aggressive histopathological variants, where, in the event of recurrence/metastasis, the disease demonstrates adverse prognosis and higher incidence of radioiodine refractoriness. At the end, certain important and noteworthy concepts pertaining to LT prescription that has definitive practical implications for the suppressive therapy in DTC patients are described.
format Online
Article
Text
id pubmed-3764683
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37646832013-09-09 A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India Basu, Sandip Abhyankar, Amit Asopa, Ramesh Chaukar, Devendra DCruz, Anil K Indian J Nucl Med Commentary In this communication, the authors discuss the issue of individualization of thyrotropin suppressive therapy in differentiated thyroid carcinoma (DTC) patients and share their views with respect to optimizing the dose of levothyroxine (LT) prescription both during discharge from radioiodine therapy ward and during follow-up. The changing management paradigm at our Institute during post-thyroidectomy period and during the preparation for radioiodine scan is also briefly highlighted. Five factors can be identified as important determinants for the dose individualization approach: (1) Persistence or absence of metastatic disease, (2) the risk characteristics of the patient and the tumor (3) patient's clinical profile, symptomatology, and contraindications (4) the feasibility to ensure a proper thyroid stimulating hormone TSH suppression level (depends on patient's socio-economic and educational background, the connectivity with the local physician and his expertise) (5) time period elapsed since initial diagnosis. While discussing each individual case scenario, the authors, based upon their experience in one of the busiest thyroid cancer referral centers in the country, discuss certain unaddressed points in the current guideline recommendations, deviations made and some challenges toward employing them into practice, which could be situation and center specific. In addition to these, the value of clinical examination, patient profile and detailed enquiry about clinical symptomatology by the attending physician in each follow-up visit cannot be overemphasized. According to the authors, this aspect, quite important for dose determination in an individual, is relatively underrepresented in the present guidelines. It would also be worthwhile to follow a conservative approach (till clear data emerges) in patients who have characteristics of “high-risk” disease, but are clinically and biochemically disease free, if no medical contraindications exist and patient tolerates the suppressive therapy well. This would be particularly applicable in the presence of aggressive histopathological variants, where, in the event of recurrence/metastasis, the disease demonstrates adverse prognosis and higher incidence of radioiodine refractoriness. At the end, certain important and noteworthy concepts pertaining to LT prescription that has definitive practical implications for the suppressive therapy in DTC patients are described. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3764683/ /pubmed/24019666 Text en Copyright: © Indian Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Basu, Sandip
Abhyankar, Amit
Asopa, Ramesh
Chaukar, Devendra
DCruz, Anil K
A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title_full A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title_fullStr A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title_full_unstemmed A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title_short A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India
title_sort logical levothyroxine dose individualization: optimization approach at discharge from radioiodine therapy ward and during follow-up in patients of differentiated thyroid carcinoma: balancing the risk based strategy and the practical issues and challenges: experience and views of a large volume referral centre in india
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764683/
https://www.ncbi.nlm.nih.gov/pubmed/24019666
work_keys_str_mv AT basusandip alogicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumere
AT abhyankaramit alogicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumere
AT asoparamesh alogicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumere
AT chaukardevendra alogicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumere
AT dcruzanilk alogicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumere
AT basusandip logicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumeref
AT abhyankaramit logicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumeref
AT asoparamesh logicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumeref
AT chaukardevendra logicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumeref
AT dcruzanilk logicallevothyroxinedoseindividualizationoptimizationapproachatdischargefromradioiodinetherapywardandduringfollowupinpatientsofdifferentiatedthyroidcarcinomabalancingtheriskbasedstrategyandthepracticalissuesandchallengesexperienceandviewsofalargevolumeref